A Phase 3 interventional study of Subcutaneous Insulin and Inhaled Insulin in Diabetes Mellitus, Type 1, sponsored by Pfizer. Terminated at 73 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-02-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.
Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is the only one that started in 2002, is one of 7 in phase 3, and was the 3rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Sam Chun Dang Pharm. Co. Ltd. · Sites in Germany
Ages 18–64 · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
University of Campania Luigi Vanvitelli · Sites in Italy
Ages 18–30
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 8 · Phase 4 10
First in 1994; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 582 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 20 across the 51 interventional studies. Of the 41 that completed or were terminated, 15 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies testing insulin in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03463564University of Campania Luigi VanvitelliInsulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients | 2026-12 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus. The drug is called EXUBERA (inhaled insulin).
This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171022 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Subcutaneous Insulin
Drug: Inhaled Insulin
Subcutaneous insulin with dose adjusted according to premeal blood glucose
Inhaled insulin with dose adjusted according to premeal blood glucose
Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
Change from Baseline: mean of (value of observed forced expiratory volume in the first second of forced exhalation \[FEV1\] in liters \[L\] at observation minus Baseline value).
Time frame: Baseline through Extension Follow-up Month 3
Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)
Number of subjects with a post-baseline Forced Expiratory Volume in One Second (FEV1) decrease of ≥ 15 % \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat FEV1 was performed.
Time frame: Month 3 through Extension Follow-up 3
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)
Change from Baseline: mean of (value of Carbon Monoxide Diffusing Capacity \[DLco\] measured in milliters/minutes/millimeters of mercury \[mL/min/mmHg\] at observation minus Baseline value).
Time frame: Baseline through Extension Follow-up Month 3
Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).
Number of subjects with a post-baseline Carbon Monoxide Diffusing Capacity (DLco) decrease of ≥ 20% \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat DLco was performed.
Time frame: Month 3 through Extension Follow-up Month 3
Annual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)
Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).
Time frame: Week -2 through Extension Follow-up Month 6 or end of study
Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)
Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of hemoglobin per year (ml/min/mmHg/yr).
Time frame: Week -2 through Extension Follow-up Month 6 or end of study
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
Change from Baseline: mean of (value of Glycosylated Hemoglobin \[HbA1c\] at observation minus Baseline value).
Time frame: Baseline through Extension Follow-up Month 3
Hypoglycemic Event Rates
A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Subject months = elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject month of treatment.
Time frame: Month 1 through Extension Month 39
Severe Hypoglycemic Event Rates
Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); and blood glucose measurement was ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Subject months = elapsed number of months subject was in study in each time interval. Crude event rate = total events divided by subject months \* 100.
Time frame: Month 1 through Extension Month 39
Change From Baseline in Fasting Plasma Glucose
Change from Baseline: mean of (value of fasting plasma glucose \[milligrams per deciliter (mg/dL)\] at observation minus Baseline value).
Time frame: Baseline through Extension Follow-up Month 3
Change From Baseline Body Weight
Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus mean baseline body weight.
Time frame: Baseline through Extension Follow-up Month 3
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)
Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight; long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
Time frame: Month 3 through Extension Month 39
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
Time frame: Month 3 through Extension Month 39
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
Time frame: Month 3 through Extension Month 39
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight
Total Daily Short-Acting Insulin Dose adjusted for body weight (milligrams \[mg\] or units divided by kilograms \[kg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
Time frame: Month 3 through Extension Month 39
Baseline Dyspnea Index (BDI)
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.
Time frame: Week - 1
Transition Dyspnea Index (TDI)
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.
Time frame: Week 4 through ,Extension Follow-up Month 6 and every 6 months thereafter or end of study
Lipids
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides measured as milligrams per deciliter (mg/dL).
Time frame: Week -4 through Month 24
Cough Questionnaire
Subject completed cough questionnaire with reference to the past 4 weeks. Six question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (subcutaneous \[SC\] or inhaled), and productivity of cough; range 0 (no symptoms) to 4 (severe symptoms). Questionnaire was administered at Week 0 and then at subsequent visits only if cough was identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.
Time frame: Week 0 and if indicated through Extension Follow up Month 3
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) measured in liters (L).
Time frame: Week -3 through Extension Follow-up Month 6 or End of Study
Total Lung Capacity (TLC)
Total Lung Capacity measured in liters (L).
Time frame: Week -3 through Extension Follow-up Month 6 or End of Study
Insulin Antibodies
Median insulin antibodies at each visit measured in micro units per milliliter (microU/mL).
Time frame: Baseline through Extension Month 39
A total of 64 centers took part in the study between 09 May 2002 and 08 December 2008.
| Milestone | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Started | 291 | 291 |
| Received study treatment | 290 | 290 |
| Completed | 192 | 198 |
| Not completed | 99 | 93 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Adverse event | 16 | 5 |
| Withdrew: Laboratory abnormality | 2 | 0 |
| Withdrew: Lack of efficacy | 13 | 1 |
| Withdrew: Lost to follow-up | 8 | 24 |
| Withdrew: Other | 23 | 19 |
| Withdrew: Withdrawal by subject | 33 | 42 |
| Withdrew: Adverse event 4 days after last dose | 1 | 0 |
| Withdrew: Withdrew prior to study treatment | 1 | 1 |
Change from Baseline: mean of (value of observed forced expiratory volume in the first second of forced exhalation \[FEV1\] in liters \[L\] at observation minus Baseline value).
| liters | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=283, 281) | 3.51 ± 0.76 | 3.47 ± 0.78 |
| Month 3 (n=277, 263) | -0.04 ± 0.12 | -0.01 ± 0.12 |
| Month 6 (n=262, 273) | -0.05 ± 0.14 | -0.03 ± 0.13 |
| Month 9 (n=251, 264) | -0.06 ± 0.14 | -0.04 ± 0.13 |
| Month 12 (n=242, 259) | -0.08 ± 0.14 | -004 ± 0.13 |
| Month 15 (n=236, 250) | -0.09 ± 0.16 | -0.05 ± 0.15 |
| Month 18 (n=227, 232) | -0.09 ± 0.15 | -0.06 ± 0.15 |
| Month 21 (n=218, 224) | -0.11 ± 0.16 | -0.06 ± 0.15 |
| Month 24 (n=211, 219) | -0.12 ± 0.17 | -0.08 ± 0.16 |
| Follow-up Month 1 (n=242, 209) | -0.11 ± 0.17 | -0.09 ± 0.16 |
| Follow-up Month 3 (n=249, 225) | -0.10 ± 0.16 | -0.09 ± 0.15 |
| Follow-up Month 6 (n=240, 218) | -0.10 ± 0.17 | -0.09 ± 0.16 |
| Extension Month 1 (n=166, 175) | -0.14 ± 0.20 | -0.10 ± 0.17 |
| Extension Month 3 (n=161, 175) | -0.14 ± 0.18 | -0.10 ± 0.18 |
| Extension Month 6 (n=158, 170) | -0.15 ± 0.19 | -0.11 ± 0.17 |
| Extension Month 9 (n=151, 164) | -0.16 ± 0.18 | -0.12 ± 0.19 |
| Extension Month 12 (n=152,161) | -0.17 ± 0.19 | -0.11 ± 0.16 |
| Extension Month 15 (n=153,162) | -0.16 ± 0.19 | -0.12 ± 0.17 |
| Extension Month 18 (n=148,160) | -0.18 ± 0.20 | -0.14 ± 0.19 |
| Extension Month 21 (n=144,158) | -0.17 ± 0.19 | -0.15 ± 0.20 |
| Extension Month 24 (n=141,153) | -0.18 ± 0.20 | -0.14 ± 0.20 |
| Extension Month 27 (n=136,146) | -0.19 ± 0.20 | -0.13 ± 0.19 |
| Extension Month 30 (n=136,147) | -0.20 ± 0.20 | -0.16 ± 0.19 |
| Extension Month 33 (n=127,139) | -0.20 ± 0.21 | -0.17 ± 0.19 |
| Extension Month 36 (n=105,126) | -0.23 ± 0.22 | -0.16 ± 0.18 |
| Extension Month 39 (n=52, 64) | -0.21 ± 0.23 | -0.17 ± 0.21 |
| Extension Month 39 (LOCF) (n=177, 187) | -0.22 ± 0.21 | -0.15 ± 0.19 |
| Extension Follow Up Month 3 (n=115,102) | -0.20 ± 0.20 | -0.17 ± 0.18 |
Number of subjects with a post-baseline Forced Expiratory Volume in One Second (FEV1) decrease of ≥ 15 % \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat FEV1 was performed.
| participants | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 3 (n=277, 263) | 0 | 0 |
| Month 6 (n=262, 273) | 0 | 0 |
| Month 9 (n=251, 264) | 0 | 1 |
| Month 12 (n=242, 259) | 1 | 0 |
| Month 15 (n=236, 250) | 3 | 1 |
| Month 18 (n=227, 232) | 0 | 3 |
| Month 21 (n=218, 224) | 2 | 3 |
| Month 24 (n=211, 219) | 3 | 2 |
| Follow-up Month 1 (n=242, 209) | 2 | 2 |
| Follow-up Month 3 (n=249, 225) | 3 | 3 |
| Follow-up Month 6 (n=240, 218) | 5 | 1 |
| Extension Month 1 (n=166, 175) | 2 | 2 |
| Extension Month 3 (n=161, 175) | 4 | 2 |
| Extension Month 6 (n=158, 170) | 2 | 2 |
| Extension Month 9 (n=151, 164) | 3 | 2 |
| Extension Month 12 (n=152, 161) | 2 | 0 |
| Extension Month 15 (n=153, 162) | 1 | 0 |
| Extension Month 18 (n=148, 160) | 4 | 3 |
| Extension Month 21 (n=144, 158) | 4 | 5 |
| Extension Month 24 (n=141, 153) | 3 | 5 |
| Extension Month 27 (n=136, 146) | 6 | 4 |
| Extension Month 30 (n=136, 147) | 6 | 2 |
| Extension Month 33 (n=127, 139) | 4 | 3 |
| Extension Month 36 (n=105, 126) | 7 | 3 |
| Extension Month 39 (n=52, 64) | 2 | 1 |
| Extension Follow Up Month 3 (n=115, 102) | 5 | 1 |
Change from Baseline: mean of (value of Glycosylated Hemoglobin \[HbA1c\] at observation minus Baseline value).
| percent | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=288, 286) | 7.41 ± 1.06 | 7.46 ± 1.06 |
| Week 6 (n=269, 256) | -0.40 ± 0.61 | -0.43 ± 0.61 |
| Month 3 (n=276, 280) | -0.36 ± 0.78 | -0.41 ± 0.73 |
| Month 6 (n=263, 274) | -0.21 ± 0.80 | -0.36 ± 0.81 |
| Month 9 (n=253, 266) | -0.10 ± 0.84 | -0.23 ± 0.81 |
| Month 12 (n=240, 262) | -0.04 ± 0.87 | -0.32 ± 0.82 |
| Month 15 (n=236, 253) | -0.12 ± 0.85 | -0.29 ± 0.90 |
| Month 18 (n=231, 237) | -0.11 ± 0.88 | -0.30 ± 0.89 |
| Month 21 (n=223, 231) | -0.05 ± 0.92 | -0.25 ± 0.92 |
| Month 24 (n=214, 225) | 0.05 ± 0.91 | -0.27 ± 0.83 |
| Follow-up Month 3 (n=205, 195) | -0.13 ± 0.87 | -0.22 ± 0.83 |
| Follow-up Month 6 (n=219, 221) | -0.10 ± 0.87 | -0.14 ± 0.87 |
| Extension Month 1 (n=171, 177) | -0.09 ± 0.90 | -0.23 ± 0.85 |
| Extension Month 3 (n=170, 177) | 0.12 ± 0.95 | -0.17 ± 0.91 |
| Extension Month 6 (n=166, 178) | 0.21 ± 0.99 | -0.19 ± 0.86 |
| Extension Month 9 (n=159, 171) | 0.26 ± 1.00 | -0.06 ± 0.94 |
| Extension Month 12 (n=158, 169) | 0.39 ± 0.98 | 0.08 ± 0.87 |
| Extension Month 15 (n=156, 167) | 0.40 ± 1.05 | 0.17 ± 0.85 |
| Extension Month 18 (n=153, 166) | 0.32 ± 0.94 | 0.05 ± 0.86 |
| Extension Month 21 (n=154, 161) | 0.27 ± 0.99 | 0.00 ± 0.88 |
| Extension Month 24 (n=149, 154) | 0.29 ± 0.89 | 0.06 ± 0.91 |
| Extension Month 27 (n=141, 151) | 0.33 ± 0.97 | 0.10 ± 0.92 |
| Extension Month 30 (n=140, 150) | 0.33 ± 0.91 | -0.01 ± 0.89 |
| Extension Month 33 (n=131, 143) | 0.40 ± 0.94 | -0.08 ± 0.92 |
| Extension Month 36 (n=108, 132) | 0.30 ± 0.99 | -0.03 ± 0.99 |
| Extension Month 39 (n=55, 66) | 0.30 ± 0.94 | -0.09 ± 1.00 |
| Extension Follow-Up Month 3 (n=120, 107) | 0.14 ± 1.00 | 0.12 ± 1.00 |
A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Subject months = elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject month of treatment.
| total events/subject months | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 1 (n=288, 286) | 7.6 | 6.3 |
| Month 2 (n=282, 286) | 5.9 | 5.5 |
| Month 3 (n=279, 285) | 5.8 | 5.3 |
| Month 4 (n=273, 282) | 4.8 | 4.6 |
| Month 5 (n=266, 280) | 4.7 | 4.4 |
| Month 6 (n=263, 277) | 4.5 | 4.2 |
| Month 7 (n=259, 275) | 4.5 | 4.3 |
| Month 8 (n=257, 273) | 4.2 | 3.8 |
| Month 9 (n=254, 272) | 3.8 | 3.7 |
| Month 10 (n=249, 270) | 4.2 | 3.9 |
| Month 11 (n=245, 269) | 3.9 | 3.4 |
| Month 12 (n=243, 267) | 3.8 | 3.8 |
| Month 13 (n=239, 265) | 3.6 | 3.5 |
| Month 14 (n=237, 260) | 3.6 | 3.6 |
| Month 15 (n=236, 258) | 3.2 | 3.3 |
| Month 16 (n=236, 256) | 3.4 | 3.5 |
| Month 17 (n=235, 252) | 3.0 | 3.1 |
| Month 18 (n=233, 250) | 3.0 | 3.1 |
| Month 19 (n=232, 250) | 3.2 | 3.0 |
| Month 20 (n=227, 245) | 3.0 | 3.2 |
| Month 21 (n=226, 244) | 3.0 | 3.0 |
| Month 22 (n=226, 243) | 2.8 | 3.1 |
| Month 23 (n=224, 238) | 2.5 | 2.9 |
| Month 24 (n=222, 229) | 2.6 | 2.5 |
| Extension Month 1 (n=177, 187) | 3.5 | 2.9 |
| Extension Month 2 (n=177, 187) | 3.6 | 2.7 |
| Extension Month 3 (n=172, 185) | 4.1 | 2.9 |
| Extension Month 4 (n=169, 182) | 3.2 | 2.6 |
| Extension Month 5 (n=169, 182) | 3.2 | 2.8 |
| Extension Month 6 (n=168, 182) | 2.8 | 2.5 |
| Extension Month 7 (n=167, 181) | 3.1 | 2.5 |
| Extension Month 8 (n=167, 178) | 2.6 | 2.8 |
| Extension Month 9 (n=165, 177) | 2.1 | 2.6 |
| Extension Month 10 (n=165, 176) | 3.1 | 2.6 |
| Extension Month 11 (n=162, 175) | 3.2 | 2.2 |
| Extension Month 12 (n=160, 175) | 3.3 | 2.5 |
| Extension Month 13 (n=158, 174) | 2.8 | 2.6 |
| Extension Month 14 (n=156, 173) | 2.9 | 2.7 |
| Extension Month 15 (n=156, 173) | 3.0 | 2.3 |
| Extension Month 16 (n=156, 172) | 3.4 | 2.4 |
| Extension Month 17 (n=156, 172) | 3.0 | 2.3 |
| Extension Month 18 (n=156, 172) | 3.0 | 2.2 |
| Extension Month 19 (n=155, 172) | 3.2 | 2.6 |
| Extension Month 20 (n=155, 170) | 2.9 | 2.1 |
| Extension Month 21 (n=155, 169) | 2.8 | 2.3 |
| Extension Month 22 (n=155, 165) | 2.8 | 2.2 |
| Extension Month 23 (n=152, 164) | 3.3 | 2.3 |
| Extension Month 24 (n=152, 163) | 2.9 | 2.1 |
| Extension Month 25 (n=150, 162) | 3.2 | 2.1 |
| Extension Month 26 (n=149, 160) | 2.7 | 2.1 |
| Extension Month 27 (n=147, 159) | 2.7 | 1.9 |
| Extension Month 28 (n=146, 158) | 2.7 | 2.3 |
| Extension Month 29 (n=145, 155) | 2.7 | 2.0 |
| Extension Month 30 (n=143, 153) | 2.5 | 1.9 |
| Extension Month 31 (n=141, 153) | 2.6 | 2.2 |
| Extension Month 32 (n=138, 152) | 2.8 | 2.1 |
| Extension Month 33 (n=136, 150) | 2.3 | 2.1 |
| Extension Month 34 (n=131, 148) | 2.0 | 2.1 |
| Extension Month 35 (n=122, 147) | 1.8 | 2.1 |
| Extension Month 36 (n=113, 138) | 1.9 | 2.4 |
| Extension Month 37 (n=88, 104) | 1.5 | 2.0 |
| Extension Month 38 (n=66, 73) | 1.8 | 1.7 |
| Extension Month 39 (n=53, 64) | 1.7 | 1.4 |
| Overall Comparative (n=288, 286) | 4.1 | 3.9 |
| Overall Extension (n=177, 187) | 2.8 | 2.4 |
Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); and blood glucose measurement was ≤49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Subject months = elapsed number of months subject was in study in each time interval. Crude event rate = total events divided by subject months \* 100.
| events / subject months * 100 | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 1 (n=288, 286) | 10.2 | 9.1 |
| Month 2 (n=282, 286) | 7.9 | 7.4 |
| Month 3 (n=279, 285) | 6.5 | 6.0 |
| Month 4 (n=273, 282) | 3.4 | 4.3 |
| Month 5 (n=266, 280) | 0.0 | 4.3 |
| Month 6 (n=263, 277) | 3.8 | 6.5 |
| Month 7 (n=259, 275) | 2.3 | 4.0 |
| Month 8 (n=257, 273) | 2.0 | 4.0 |
| Month 9 (n=254, 272) | 4.0 | 5.2 |
| Month 10 (n=249, 270) | 0.8 | 3.3 |
| Month 11 (n=245, 269) | 2.1 | 3.0 |
| Month 12 (n=243, 267) | 2.5 | 3.8 |
| Month 13 (n=239, 265) | 1.3 | 2.7 |
| Month 14 (n=237, 260) | 1.3 | 3.5 |
| Month 15 (n=236, 258) | 1.7 | 3.1 |
| Month 16 (n=236, 256) | 2.6 | 2.0 |
| Month 17 (n=235, 252) | 3.9 | 1.6 |
| Month 18 (n=233, 250) | 2.6 | 5.6 |
| Month 19 (n=232, 250) | 0.4 | 2.4 |
| Month 20 (n=227, 245) | 0.4 | 4.9 |
| Month 21 (n=226, 244) | 1.8 | 2.9 |
| Month 22 (n=226, 243) | 0.9 | 2.1 |
| Month 23 (n=224, 238) | 0.9 | 2.6 |
| Month 24 (n=222, 239) | 0.8 | 2.6 |
| Extension Month 1 (n=177, 187) | 3.9 | 1.2 |
| Extension Month 2 (n=177, 187) | 4.0 | 7.0 |
| Extension Month 3 (n=172, 185) | 4.0 | 2.4 |
| Extension Month 4 (n=169, 182) | 1.4 | 1.2 |
| Extension Month 5 (n=169, 182) | 2.7 | 4.2 |
| Extension Month 6 (n=168, 182) | 0.0 | 3.0 |
| Extension Month 7 (n=167, 181) | 0.7 | 2.4 |
| Extension Month 8 (n=167, 178) | 0.0 | 2.4 |
| Extension Month 9 (n=165, 177) | 2.1 | 4.9 |
| Extension Month 10 (n=165, 176) | 0.0 | 3.0 |
| Extension Month 11 (n=162, 175) | 2.8 | 1.2 |
| Extension Month 12 (n=160, 175) | 1.4 | 4.3 |
| Extension Month 13 (n=158, 174) | 0.7 | 1.8 |
| Extension Month 14 (n=156, 173) | 1.4 | 3.1 |
| Extension Month 15 (n=156, 173) | 1.4 | 11.1 |
| Extension Month 16 (n=156, 172) | 0.7 | 13.7 |
| Extension Month 17 (n=156, 172) | 0.7 | 5.6 |
| Extension Month 18 (n=156, 172) | 0.0 | 7.5 |
| Extension Month 19 (n=155, 172) | 1.4 | 6.9 |
| Extension Month 20 (n=155, 170) | 2.1 | 2.5 |
| Extension Month 21 (n=155, 169) | 1.4 | 3.8 |
| Extension Month 22 (n=155, 165) | 2.1 | 1.3 |
| Extension Month 23 (n=152, 164) | 1.4 | 3.2 |
| Extension Month 24 (n=152, 163) | 0.7 | 3.2 |
| Extension Month 25 (n=150, 162) | 1.5 | 0.0 |
| Extension Month 26 (n=149, 160) | 2.2 | 0.7 |
| Extension Month 27 (n=147, 159) | 0.7 | 0.0 |
| Extension Month 28 (n=146, 158) | 0.0 | 3.4 |
| Extension Month 29 (n=145, 155) | 0.0 | 0.7 |
| Extension Month 30 (n=143, 153) | 0.8 | 0.7 |
| Extension Month 31 (n=141, 153) | 3.1 | 0.0 |
| Extension Month 32 (n=138, 152) | 0.0 | 1.4 |
| Extension Month 33 (n=136, 150) | 2.4 | 1.4 |
| Extension Month 34 (n=131, 148) | 0.8 | 1.4 |
| Extension Month 35 (n=122, 147) | 0.0 | 5.9 |
| Extension Month 36 (n=113, 138) | 1.0 | 0.9 |
| Extension Month 37 (n=88, 104) | 0.0 | 3.8 |
| Extension Month 38 (n=66, 73) | 0.0 | 0.0 |
| Extension Month 39 (n=53, 64) | 0.8 | 1.7 |
| Overall Comparative (n=288, 286) | 2.8 | 4.1 |
| Overall Extension (n=177, 187) | 1.4 | 3.3 |
Change from Baseline: mean of (value of fasting plasma glucose \[milligrams per deciliter (mg/dL)\] at observation minus Baseline value).
| mg/dL | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=286, 286) | 171.24 ± 63.20 | 170.06 ± 55.20 |
| Week 6 (n=263, 250) | -26.04 ± 84.79 | -14.02 ± 80.13 |
| Month 3 (n=267, 276) | -21.84 ± 85.26 | -6.15 ± 79.08 |
| Month 6 (n=258, 271) | -31.48 ± 81.62 | -6.29 ± 83.81 |
| Month 9 (n=243, 262) | -25.34 ± 86.24 | 1.28 ± 96.32 |
| Month 12 (n=232, 256) | -24.25 ± 87.53 | -4.95 ± 85.96 |
| Month 15 (n=230, 251) | -34.75 ± 83.72 | 5.96 ± 89.39 |
| Month 18 (n=226, 236) | -24.13 ± 86.44 | -8.13 ± 88.83 |
| Month 21 (n=216, 230) | -26.77 ± 88.96 | -11.62 ± 82.98 |
| Month 24 (n=208, 222) | -18.36 ± 92.92 | 1.25 ± 84.87 |
| Follow-up Month 3 (n=2, 2) | -43.50 ± 85.09 | 46.67 ± 24.04 |
| Follow-up Month 6 (n=159, 164) | 3.45 ± 80.26 | 1.46 ± 85.49 |
| Extension Month 1 (n=164, 171) | -25.52 ± 90.15 | -2.72 ± 91.27 |
| Extension Month 3 (n=167, 172) | -25.02 ± 87.75 | 0.43 ± 84.55 |
| Extension Month 6 (n=164, 177) | -13.47 ± 80.85 | -12.56 ± 86.93 |
| Extension Month 9 (n=152, 170) | -16.19 ± 94.12 | -4.46 ± 88.86 |
| Extension Month 12 (n=155, 167) | -22.53 ± 83.01 | -5.15 ± 81.38 |
| Extension Month 15 (n=148, 163) | -26.11 ± 85.78 | -10.64 ± 86.00 |
| Extension Month 18 (n=148, 163) | -12.42 ± 86.69 | -2.32 ± 84.41 |
| Extension Month 21 (n=152, 157) | -24.75 ± 87.29 | 4.86 ± 89.31 |
| Extension Month 24 (n=142, 148) | -20.46 ± 86.45 | -10.36 ± 93.08 |
| Extension Month 27 (n=140, 148) | -14.91 ± 78.42 | -2.86 ± 91.97 |
| Extension Month 30 (n=138, 147) | -17.16 ± 86.47 | -3.77 ± 86.15 |
| Extension Month 33 (n=129, 141) | -22.77 ± 94.77 | -12.12 ± 88.26 |
| Extension Month 36 (n=107, 132) | -20.00 ± 81.03 | -2.49 ± 86.06 |
| Extension Month 39 (n=55, 64) | -38.47 ± 95.17 | -1.57 ± 78.47 |
| Extension Follow-Up Month 3 (n=118, 105) | 1.97 ± 95.39 | 3.25 ± 84.53 |
Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus mean baseline body weight.
| kilograms | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=288, 286) | 75.12 ± 13.57 | 73.72 ± 13.13 |
| Week 4 (n=257, 247) | 0.30 ± 1.39 | 0.63 ± 3.01 |
| Week 8 (n=263, 262) | 0.46 ± 1.88 | 0.67 ± 2.00 |
| Month 3 (n=273, 269) | 0.13 ± 2.20 | 0.67 ± 2.35 |
| Week 18 (n=248, 260) | 0.15 ± 2.60 | 1.00 ± 2.64 |
| Month 6 (n=259, 272) | 0.11 ± 2.89 | 1.25 ± 3.08 |
| Month 9 (n=251, 266) | 0.05 ± 3.28 | 1.41 ± 3.35 |
| Month 12 (n=242, 259) | 0.37 ± 3.46 | 1.55 ± 3.59 |
| Month 15 (n=236, 250) | 0.44 ± 3.57 | 1.84 ± 3.90 |
| Month 18 (n=227, 233) | 0.57 ± 3.99 | 2.26 ± 4.30 |
| Month 21 (n=220, 224) | 1.07 ± 4.22 | 2.35 ± 4.51 |
| Month 24 (n=211, 220) | 0.99 ± 4.58 | 2.23 ± 4.58 |
| Follow-up Month 3 (n=248, 225) | 1.50 ± 4.24 | 2.31 ± 4.89 |
| Follow-up Month 6 (n=239, 219) | 1.68 ± 4.28 | 2.17 ± 4.46 |
| Extension Month 1 (n=166, 175) | 2.44 ± 6.98 | 2.50 ± 4.93 |
| Extension Month 3 (n=161, 175) | 1.73 ± 4.69 | 3.08 ± 7.17 |
| Extension Month 6 (n=158, 170) | 1.67 ± 4.93 | 3.05 ± 4.75 |
| Extension Month 9 (n=153, 164) | 1.61 ± 4.73 | 3.17 ± 5.27 |
| Extension Month 12 (n=152, 162) | 2.11 ± 4.95 | 3.08 ± 4.93 |
| Extension Month 15 (n=153, 162) | 2.01 ± 5.06 | 3.16 ± 5.21 |
| Extension Month 18 (n=149, 160) | 2.31 ± 5.50 | 3.30 ± 5.82 |
| Extension Month 21 (n=144, 158) | 2.14 ± 5.63 | 3.72 ± 5.82 |
| Extension Month 24 (n=141, 153) | 2.49 ± 5.98 | 4.23 ± 5.70 |
| Extension Month 27 (n=136, 146) | 2.12 ± 5.87 | 3.96 ± 6.15 |
| Extension Month 30 (n=136, 147) | 2.42 ± 6.25 | 4.80 ± 8.38 |
| Extension Month 33 (n=127, 139) | 2.30 ± 5.96 | 5.28 ± 10.84 |
| Extension Month 36 (n=105, 126) | 2.11 ± 6.24 | 3.87 ± 6.25 |
| Extension Month 39 (n=52, 64) | 1.58 ± 7.90 | 4.83 ± 6.75 |
| Extension Follow-Up Month 3 (n=116, 103) | 2.49 ± 5.98 | 4.09 ± 6.34 |
Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight; long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
| units | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 3 (n=280, 285) | 30.52 ± 16.00 | 34.97 ± 17.38 |
| Month 6 (n=271, 280) | 30.57 ± 16.48 | 35.37 ± 17.72 |
| Month 9 (n=256, 269) | 30.69 ± 16.53 | 35.35 ± 18.06 |
| Month 12 (n=243, 262) | 30.65 ± 17.29 | 35.42 ± 18.00 |
| Month 15 (n=237, 255) | 30.99 ± 17.83 | 35.75 ± 17.86 |
| Month 18 (n=234, 242) | 30.97 ± 17.86 | 36.35 ± 18.13 |
| Month 21 (n=224, 233) | 31.30 ± 18.53 | 36.75 ± 17.76 |
| Month 24 (n=218, 229) | 31.82 ± 19.36 | 36.21 ± 18.02 |
| Extension Month 1 (n=171, 178) | 32.84 ± 18.90 | 35.67 ± 18.72 |
| Extension Month 3 (n=170, 177) | 32.45 ± 18.91 | 35.10 ± 18.07 |
| Extension Month 6 (n=166, 179) | 31.96 ± 18.36 | 34.75 ± 17.55 |
| Extension Month 9 (n=160, 174) | 32.73 ± 19.24 | 35.22 ± 17.41 |
| Extension Month 12 (n=159, 169) | 32.29 ± 19.12 | 33.82 ± 15.65 |
| Extension Month 15 (n=156, 164) | 32.02 ± 18.61 | 35.52 ± 18.37 |
| Extension Month 18 (n=152, 166) | 32.37 ± 18.62 | 34.88 ± 17.44 |
| Extension Month 21 (n=154, 165) | 31.83 ± 19.05 | 35.14 ± 17.24 |
| Extension Month 24 (n=150, 153) | 31.99 ± 19.59 | 35.61 ± 18.34 |
| Extension Month 27 (n=142, 153) | 31.25 ± 19.01 | 35.58 ± 18.42 |
| Extension Month 30 (n=141, 148) | 31.06 ± 19.73 | 35.34 ± 18.73 |
| Extension Month 33 (n=133, 144) | 30.71 ± 19.06 | 34.83 ± 17.47 |
| Extension Month 36 (n=113, 136) | 29.62 ± 19.06 | 33.58 ± 15.64 |
| Extension Month 39 (n=57, 67) | 29.07 ± 16.59 | 33.63 ± 19.79 |
Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included NPH Insulin, Ultralente, and Insulin Glargine for both groups.
| units/kg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 3 (n=280, 285) | 0.41 ± 0.22 | 0.48 ± 0.25 |
| Month 6 (n=271, 280) | 0.41 ± 0.23 | 0.49 ± 0.25 |
| Month9 (n=256, 269) | 0.41 ± 0.23 | 0.49 ± 0.26 |
| Month 12 (n=243, 262) | 0.41 ± 0.24 | 0.49 ± 0.26 |
| Month 15 (n=237, 255) | 0.42 ± 0.25 | 0.49 ± 0.25 |
| Month 18 (n=234, 242) | 0.42 ± 0.25 | 0.50 ± 0.26 |
| Month 21 (n=224, 233) | 0.42 ± 0.26 | 0.51 ± 0.26 |
| Month 24 (n=218, 229) | 0.43 ± 0.27 | 0.50 ± 0.26 |
| Extension Month 1 (n=171, 178) | 0.45 ± 0.25 | 0.49 ± 0.27 |
| Extension Month 3 (n=170, 177) | 0.44 ± 0.25 | 0.49 ± 0.26 |
| Extension Month 6 (n=166, 179) | 0.43 ± 0.24 | 0.48 ± 0.26 |
| Extension Month 9 (n=160, 174) | 0.44 ± 0.25 | 0.49 ± 0.25 |
| Extension Month 12 (n=159, 169) | 0.44 ± 0.24 | 0.47 ± 0.22 |
| Extension Month 15 (n=156, 164) | 0.44 ± 0.25 | 0.49 ± 0.26 |
| Extension Month 18 (n=152, 166) | 0.44 ± 0.25 | 0.48 ± 0.24 |
| Extension Month 21 (n=154, 165) | 0.44 ± 0.25 | 0.48 ± 0.23 |
| Extension Month 24 (n=150, 153) | 0.44 ± 0.26 | 0.49 ± 0.25 |
| Extension Month 27 (n=142, 153) | 0.43 ± 0.24 | 0.49 ± 0.24 |
| Extension Month 30 (n=141, 148) | 0.42 ± 0.26 | 0.49 ± 0.26 |
| Extension Month 33 (n=133, 144) | 0.42 ± 0.25 | 0.48 ± 0.23 |
| Extension Month 36 (n=113, 136) | 0.40 ± 0.25 | 0.46 ± 0.21 |
| Extension Month 39 (n=57, 67) | 0.39 ± 0.23 | 0.45 ± 0.25 |
Total daily dose of short-acting insulin unadjusted for body weight. Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
| mg, units | Inhaled Insulin (mg) | Subcutaneous Insulin (Units) |
|---|---|---|
| Month 3 (n=280, 285) | 10.45 ± 5.71 | 25.05 ± 14.73 |
| Month 6 (n=271, 281) | 11.50 ± 6.73 | 25.14 ± 14.72 |
| Month 9 (n=257, 271) | 11.97 ± 6.79 | 24.90 ± 14.54 |
| Month 12 (n=243, 266) | 12.69 ± 6.96 | 25.32 ± 14.35 |
| Month 15 (n=237, 255) | 13.12 ± 7.65 | 25.11 ± 14.83 |
| Month 18 (n=234, 241) | 13.60 ± 8.04 | 25.20 ± 15.15 |
| Month 21 (n=224, 235) | 14.42 ± 8.64 | 25.45 ± 15.41 |
| Month 24 (n=219, 232) | 14.61 ± 9.14 | 25.23 ± 16.57 |
| Extension Month 1 (n=170, 179) | 11.49 ± 6.35 | 25.84 ± 17.48 |
| Extension Month 3 (n=170, 178) | 12.50 ± 6.88 | 25.94 ± 18.26 |
| Extension Month 6 (n=166, 179) | 13.64 ± 9.07 | 25.39 ± 17.52 |
| Extension Month 9 (n=160, 174) | 14.06 ± 9.33 | 26.19 ± 18.00 |
| Extension Month 12 (n=159, 169) | 14.74 ± 10.07 | 25.49 ± 17.69 |
| Extension Month 15 (n=156, 167) | 13.93 ± 8.38 | 25.80 ± 17.62 |
| Extension Month 18 (n=153, 167) | 13.97 ± 8.58 | 26.04 ± 17.52 |
| Extension Month 21 (n=154, 166) | 14.53 ± 8.80 | 25.95 ± 17.04 |
| Extension Month 24 (n=150, 156) | 14.48 ± 8.71 | 27.26 ± 19.48 |
| Extension Month 27 (n=142, 153) | 14.82 ± 8.70 | 26.63 ± 17.82 |
| Extension Month 30 (n=141, 149) | 14.92 ± 8.93 | 27.22 ± 18.66 |
| Extension Month 33 (n=133, 144) | 15.28 ± 9.72 | 26.71 ± 18.67 |
| Extension Month 36 (n=113, 136) | 15.72 ± 8.32 | 27.04 ± 19.65 |
| Extension Month 39 (n=57, 67) | 17.92 ± 12.04 | 29.75 ± 19.68 |
Total Daily Short-Acting Insulin Dose adjusted for body weight (milligrams \[mg\] or units divided by kilograms \[kg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.
| mg/kg, units/kg | Inhaled Insulin (mg/kg) | Subcutaneous Insulin (Units/kg) |
|---|---|---|
| Month 3 (n=280, 285) | 0.14 ± 0.07 | 0.34 ± 0.19 |
| Month 6 (n=271, 281) | 0.15 ± 0.08 | 0.34 ± 0.19 |
| Month 9 (n=257, 271) | 0.16 ± 0.09 | 0.34 ± 0.18 |
| Month 12 (n=243, 266) | 0.17 ± 0.09 | 0.34 ± 0.18 |
| Month 15 (n=237, 255) | 0.17 ± 0.10 | 0.34 ± 0.19 |
| Month 18 (n=234, 241) | 0.18 ± 0.10 | 0.34 ± 0.19 |
| Month 21 (n=224, 235) | 0.19 ± 0.11 | 0.34 ± 0.20 |
| Month 24 (n=219, 232) | 0.19 ± 0.12 | 0.34 ± 0.21 |
| Extension Month 1 (n=170, 179) | 0.15 ± 0.08 | 0.35 ± 0.22 |
| Extension Month 3 (n=170, 178) | 0.17 ± 0.08 | 0.35 ± 0.23 |
| Extension Month 6 (n=166, 179) | 0.18 ± 0.10 | 0.34 ± 0.22 |
| Extension Month 9 (n=160, 174) | 0.19 ± 0.11 | 0.35 ± 0.22 |
| Extension Month 12 (n=159, 169) | 0.20 ± 0.13 | 0.34 ± 0.22 |
| Extension Month 15 (n=156, 167) | 0.19 ± 0.10 | 0.35 ± 0.22 |
| Extension Month 18 (n=153, 167) | 0.19 ± 0.10 | 0.35 ± 0.22 |
| Extension Month 21 (n=154, 166) | 0.19 ± 0.11 | 0.35 ± 0.22 |
| Extension Month 24 (n=150, 156) | 0.20 ± 0.11 | 0.36 ± 0.24 |
| Extension Month 27 (n=142, 153) | 0.20 ± 0.11 | 0.36 ± 0.23 |
| Extension Month 30 (n=141, 149) | 0.20 ± 0.11 | 0.37 ± 0.24 |
| Extension Month 33 (n=133, 144) | 0.20 ± 0.12 | 0.36 ± 0.24 |
| Extension Month 36 (n=113, 136) | 0.21 ± 0.11 | 0.36 ± 0.25 |
| Extension Month 39 (n=57, 67) | 0.23 ± 0.14 | 0.39 ± 0.23 |
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI score range 0 (very severe impairment) to 4 (no impairment) scaled to a BDI focal score (0-12). Lower score indicates greater impairment.
No measurements were reported for this outcome.
Clinician administered instrument to measure the baseline severity of breathlessness (shortness of breath) in symptomatic patients with 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI score range -3 (major deterioration) to +3 (major improvement); sum of all domains yields the TDI focal score (-9 to +9); lower score indicates greater deterioration. Compared to previous scoring to determine deterioration or improvement.
No measurements were reported for this outcome.
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides measured as milligrams per deciliter (mg/dL).
No measurements were reported for this outcome.
Subject completed cough questionnaire with reference to the past 4 weeks. Six question instrument to measure cough frequency (night, day), severity, timing in relation to short-acting insulin dosing, severity related to insulin dosing (subcutaneous \[SC\] or inhaled), and productivity of cough; range 0 (no symptoms) to 4 (severe symptoms). Questionnaire was administered at Week 0 and then at subsequent visits only if cough was identified as an adverse event not explained by a concomitant condition, such as an upper respiratory tract infection.
No measurements were reported for this outcome.
Change from Baseline: mean of (value of Carbon Monoxide Diffusing Capacity \[DLco\] measured in milliters/minutes/millimeters of mercury \[mL/min/mmHg\] at observation minus Baseline value).
| mL/min/mmHg | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=283, 281) | 28.09 ± 6.20 | 27.18 ± 6.40 |
| Month 3 (n=277, 264) | -1.09 ± 1.73 | -0.29 ± 1.71 |
| Month 6 (n=262, 273) | -1.17 ± 2.16 | -0.26 ± 1.85 |
| Month 9 (n=250, 266) | -1.16 ± 2.09 | -0.41 ± 1.91 |
| Month 12 (n=241, 258) | -1.40 ± 2.15 | -0.41 ± 2.15 |
| Month 15 (n=235, 249) | -1.16 ± 2.17 | -0.42 ± 2.17 |
| Month 18 (n=227, 232) | -1.21 ± 2.28 | -0.45 ± 2.22 |
| Month 21 (n=218, 224) | -1.29 ± 2.49 | -0.56 ± 2.07 |
| Month 24 (n=208, 219) | -1.28 ± 2.29 | -0.71 ± 2.40 |
| Follow-up Month 1 (n=242,208) | -0.81 ± 2.20 | -0.81 ± 2.42 |
| Follow-up Month 3 (n=247,225) | -0.77 ± 2.46 | -0.80 ± 2.10 |
| Follow-up Month 6 (n=240,218) | -0.77 ± 2.36 | -0.67 ± 2.28 |
| Extension Month 1 (n=166,175) | -1.15 ± 2.54 | -0.55 ± 2.35 |
| Extension Month 3 (n=161,173) | -1.43 ± 2.37 | -0.73 ± 2.45 |
| Extension Month 6 (n=158,169) | -1.38 ± 2.37 | -0.78 ± 2.54 |
| Extension Month 9 (n=151,163) | -1.17 ± 2.52 | -0.74 ± 2.57 |
| Extension Month 12 (n=152,161) | -1.70 ± 2.46 | -0.70 ± 2.60 |
| Extension Month 15 (n=143,160) | -1.70 ± 2.27 | -0.72 ± 2.94 |
| Extension Month 18 (n=148,159) | -1.67 ± 2.36 | -1.02 ± 2.72 |
| Extension Month 21 (n=144,156) | -1.51 ± 2.59 | -0.88 ± 2.64 |
| Extension Month 24 (n=140,152) | -1.63 ± 2.46 | -0.70 ± 2.72 |
| Extension Month 27 (n=136,144) | -1.25 ± 2.65 | -0.76 ± 2.75 |
| Extension Month 30 (n=135,146) | -1.36 ± 2.54 | -0.75 ± 2.59 |
| Extension Month 33 (n=127,139) | -1.31 ± 2.54 | -0.81 ± 2.55 |
| Extension Month 36 (n=105,122) | -1.53 ± 2.53 | -0.96 ± 2.82 |
| Extension Month 39 (n=52, 64) | -2.02 ± 3.72 | -0.93 ± 2.59 |
| Extension Month 39 (LOCF) (n=177, 187) | -1.66 ± 2.90 | -0.90 ± 2.55 |
| Extension Follow Up Month 3 (n=115, 101) | -0.89 ± 2.35 | -1.11 ± 2.59 |
Number of subjects with a post-baseline Carbon Monoxide Diffusing Capacity (DLco) decrease of ≥ 20% \[(baseline observed value minus visit observed value)/(baseline observed value) \* 100\]; in the absence of an obvious intercurrent illness, a repeat DLco was performed.
| participants | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Month 3 (n=277, 264) | 0 | 1 |
| Month 6 (n=262, 273) | 1 | 0 |
| Month 9 (n=250, 266) | 2 | 1 |
| Month 12 (n=241, 258) | 2 | 1 |
| Month 15 (n=235, 249) | 1 | 2 |
| Month 18 (n=227, 232) | 5 | 4 |
| Month 21 (n=218, 224) | 4 | 2 |
| Month 24 (n=208, 219) | 2 | 2 |
| Follow-up Month 1 (n=242, 208) | 3 | 3 |
| Follow-up Month 3 (n=247, 225) | 1 | 1 |
| Follow-up Month 6 (n=240, 218) | 1 | 2 |
| Extension Month 1 (n=166, 175) | 5 | 0 |
| Extension Month 3 (n=161, 173) | 4 | 1 |
| Extension Month 6 (n=158, 169) | 4 | 2 |
| Extension Month 9 (n=151, 163) | 2 | 2 |
| Extension Month 12 (n=152, 161) | 5 | 2 |
| Extension Month 15 (n=143, 160) | 3 | 2 |
| Extension Month 18 (n=148, 159) | 1 | 4 |
| Extension Month 21 (n=144, 156) | 5 | 3 |
| Extension Month 24 (n=140, 152) | 5 | 1 |
| Extension Month 27 (n=136, 144) | 4 | 2 |
| Extension Month 30 (n=135, 146) | 4 | 4 |
| Extension Month 33 (n=127, 139) | 3 | 2 |
| Extension Month 36 (n=105, 122) | 4 | 7 |
| Extension Month 39 (n=52, 64) | 3 | 1 |
| Extension Follow Up Month 3 (n=115, 101) | 3 | 2 |
Forced Vital Capacity (FVC) measured in liters (L).
No measurements were reported for this outcome.
Total Lung Capacity measured in liters (L).
No measurements were reported for this outcome.
Annual rate of change in FEV1 calculated as slope over time \[visit\] for forced expiratory volume in 1 second measured as liters per year (L/yr).
No measurements were reported for this outcome.
Annual rate of change in DLco calculated as slope over time (visit) measured as milliliters per minute per millimeters of hemoglobin per year (ml/min/mmHg/yr).
No measurements were reported for this outcome.
Median insulin antibodies at each visit measured in micro units per milliliter (microU/mL).
| microU/mL | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| Baseline (n=284, 283) | 4.50 (1.05 to 3514.00) | 4.10 (1.05 to 1324.00) |
| Week 3 (n=262, 260) | 7.50 (1.05 to 6056.00) | 3.60 (1.05 to 828.00) |
| Week 6 (n=267, 260) | 15.00 (1.05 to 12445.00) | 4.00 (1.05 to 1792.00) |
| Month 3 (n=271, 274) | 31.00 (1.05 to 4108.00) | 4.25 (1.05 to 876.00) |
| Week 18 (n=263, 271) | 49.00 (1.05 to 1968.00) | 4.40 (1.05 to 1012.00) |
| Month 6 (n=254, 268) | 88.50 (1.05 to 1420.00) | 5.10 (1.05 to 1352.00) |
| Month 9 (n=244, 262) | 134.50 (1.05 to 2776.00) | 4.95 (1.05 to 1608.00) |
| Month 12 (n=234, 258) | 142.50 (1.05 to 3156.00) | 4.90 (1.05 to 2192.00) |
| Month 15 (n=230, 250) | 109.50 (1.05 to 4380.00) | 4.70 (1.05 to 1360.00) |
| Month 18 (n=226, 233) | 91.00 (1.05 to 2390.00) | 4.40 (1.05 to 1655.00) |
| Month 21 (n=216, 228) | 59.50 (1.05 to 2575.00) | 3.85 (1.05 to 932.00) |
| Month 24 (n=212, 224) | 67.00 (1.05 to 2360.00) | 4.40 (1.05 to 1420.00) |
| Follow-up Month 1 (n=234, 209) | 41.50 (1.05 to 27286.00) | 4.20 (1.05 to 1285.00) |
| Follow-up Month 3 (n=245, 226) | 28.00 (1.05 to 8119.00) | 4.20 (1.05 to 382.00) |
| Follow-up Month 6 (n=239, 223) | 22.00 (1.05 to 5280.00) | 4.40 (1.05 to 1265.00) |
| Extension Month 1 (n=164, 176) | 37.50 (1.05 to 3985.00) | 4.50 (1.05 to 900.00) |
| Extension Month 3 (165, 177) | 45.00 (1.05 to 3405.00) | 4.40 (1.05 to 1260.00) |
| Extension Month 6 (n=162, 176) | 42.50 (1.05 to 3145.00) | 3.55 (1.05 to 720.00) |
| Extension Month 9 (n=154, 167) | 41.00 (1.05 to 2465.00) | 4.70 (1.05 to 873.00) |
| Extension Month 12 (n=155, 167) | 49.00 (1.05 to 3280.00) | 4.30 (1.05 to 1310.00) |
| Extension Month 15 (n=149, 163) | 43.00 (1.05 to 3955.00) | 4.50 (1.05 to 1330.00) |
| Extension Month 18 (n=149, 160) | 45.00 (1.05 to 10755.00) | 3.60 (1.05 to 1430.00) |
| Extension Month 21 (n=151, 157) | 44.00 (1.05 to 3200.00) | 3.60 (1.05 to 820.00) |
| Extension Month 24 (n=146, 153) | 42.50 (1.05 to 3920.00) | 4.40 (1.05 to 758.00) |
| Extension Month 27 (n=138, 148) | 35.00 (1.05 to 3040.00) | 6.35 (1.05 to 1121.00) |
| Extension Month 30 (n=139, 150) | 36.00 (1.05 to 3730.00) | 5.25 (1.05 to 1110.00) |
| Extension Month 33 (n=129, 142) | 35.00 (1.05 to 3980.00) | 4.30 (1.05 to 845.00) |
| Extension Month 36 (n=104, 132) | 30.50 (1.05 to 1477.00) | 3.65 (1.05 to 876.00) |
| Extension Month 39 (n=54, 66) | 25.50 (1.05 to 1750.00) | 1.58 (1.05 to 742.00) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Insulin | — | 50/290 (17.2%) | 290/290 (100%) |
| Subcutaneous Insulin | — | 65/290 (22.4%) | 289/290 (99.7%) |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 17/290 | 26/290 |
| Coronary artery diseaseCardiac disorders | 1/290 | 4/290 |
| Chest painGeneral disorders | 4/290 | 2/290 |
| CholelithiasisHepatobiliary disorders | 2/290 | 1/290 |
| AppendicitisInfections and infestations | 0/290 | 2/290 |
| PneumoniaInfections and infestations | 1/290 | 2/290 |
| Ankle fractureInjury, poisoning and procedural complications | 2/290 | 0/290 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/290 | 1/290 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/290 | 2/290 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/290 | 1/290 |
| Event | Inhaled Insulin | Subcutaneous Insulin |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 282/290 | 285/290 |
| CoughRespiratory, thoracic and mediastinal disorders | 130/290 | 53/290 |
| Upper respiratory tract infectionInfections and infestations | 124/290 | 105/290 |
| NasopharyngitisInfections and infestations | 96/290 | 111/290 |
| InfluenzaInfections and infestations | 84/290 | 85/290 |
| SinusitisInfections and infestations | 50/290 | 47/290 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 35/290 | 47/290 |
| HeadacheNervous system disorders | 41/290 | 46/290 |
| TremorNervous system disorders | 42/290 | 43/290 |
| DiarrhoeaGastrointestinal disorders | 36/290 | 28/290 |
| Age, Customized(years) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| 18 to 25 | 48 | 53 | 101 |
| 26 to 35 | 81 | 96 | 177 |
| 36 to 45 | 94 | 71 | 165 |
| 46 to 55 | 52 | 48 | 100 |
| 56 to 65 | 15 | 22 | 37 |
| Sex: Female, Male(Participants) | Inhaled Insulin | Subcutaneous Insulin | Total |
|---|---|---|---|
| Female | 121 | 129 | 250 |
| Male | 169 | 161 | 330 |
The record gives a start of May 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin